CN105899527A - 重组润滑素的制备 - Google Patents

重组润滑素的制备 Download PDF

Info

Publication number: CN105899527A
Authority: CN; China
Prior art keywords: lubricin; glycoprotein; composition; cartilage; friction
Prior art date: 2013-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201480065482.7A

Other languages

English (en)

Chinese (zh)

Inventor

T·施密特

G·D·杰伊

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Singularis Inc

Lubris LLC

Original Assignee

Singularis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-22

Filing date

2014-10-22

Publication date

2016-08-24

2014-10-22 Application filed by Singularis Inc filed Critical Singularis Inc

2016-08-24 Publication of CN105899527A publication Critical patent/CN105899527A/zh

Status Pending legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 19
108010009030 lubricin Proteins 0.000 title claims description 58
102100028965 Proteoglycan 4 Human genes 0.000 title claims description 29
230000013595 glycosylation Effects 0.000 claims abstract description 30
238000006206 glycosylation reaction Methods 0.000 claims abstract description 28
230000001050 lubricating effect Effects 0.000 claims abstract description 22
101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 59
238000000034 method Methods 0.000 claims description 50
238000012360 testing method Methods 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 40
239000001963 growth medium Substances 0.000 claims description 39
241000283690 Bos taurus Species 0.000 claims description 27
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 26
230000014509 gene expression Effects 0.000 claims description 26
229920002674 hyaluronan Polymers 0.000 claims description 26
229960003160 hyaluronic acid Drugs 0.000 claims description 26
239000000314 lubricant Substances 0.000 claims description 25
108090000288 Glycoproteins Proteins 0.000 claims description 22
102000003886 Glycoproteins Human genes 0.000 claims description 22
108090000623 proteins and genes Proteins 0.000 claims description 22
239000000243 solution Substances 0.000 claims description 22
230000003068 static effect Effects 0.000 claims description 21
108010077544 Chromatin Proteins 0.000 claims description 19
210000003483 chromatin Anatomy 0.000 claims description 19
210000001519 tissue Anatomy 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 11
241000894007 species Species 0.000 claims description 11
239000011159 matrix material Substances 0.000 claims description 10
239000002609 medium Substances 0.000 claims description 9
108020004707 nucleic acids Proteins 0.000 claims description 9
102000039446 nucleic acids Human genes 0.000 claims description 9
150000007523 nucleic acids Chemical class 0.000 claims description 9
230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 claims description 9
241000699802 Cricetulus griseus Species 0.000 claims description 8
125000003275 alpha amino acid group Chemical group 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
210000001672 ovary Anatomy 0.000 claims description 7
239000013598 vector Substances 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 3
238000004113 cell culture Methods 0.000 claims description 3
210000002808 connective tissue Anatomy 0.000 claims description 2
102000054055 human PRG4 Human genes 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
238000009256 replacement therapy Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
230000009087 cell motility Effects 0.000 claims 1
230000017455 cell-cell adhesion Effects 0.000 claims 1
238000001356 surgical procedure Methods 0.000 claims 1
230000000699 topical effect Effects 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 6
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
238000005461 lubrication Methods 0.000 description 120
210000000845 cartilage Anatomy 0.000 description 30
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
239000000047 product Substances 0.000 description 22
238000000746 purification Methods 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
239000011780 sodium chloride Substances 0.000 description 17
210000001179 synovial fluid Anatomy 0.000 description 16
239000012530 fluid Substances 0.000 description 14
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
238000012216 screening Methods 0.000 description 14
239000000178 monomer Substances 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
238000001890 transfection Methods 0.000 description 13
229920001282 polysaccharide Polymers 0.000 description 12
239000005017 polysaccharide Substances 0.000 description 12
101100409185 Homo sapiens PRG4 gene Proteins 0.000 description 11
239000000539 dimer Substances 0.000 description 11
125000004395 glucoside group Chemical group 0.000 description 11
150000004676 glycans Chemical class 0.000 description 10
239000007788 liquid Substances 0.000 description 10
230000033001 locomotion Effects 0.000 description 10
239000004094 surface-active agent Substances 0.000 description 10
239000004202 carbamide Substances 0.000 description 9
235000013877 carbamide Nutrition 0.000 description 9
238000010586 diagram Methods 0.000 description 9
229920001213 Polysorbate 20 Polymers 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
230000008569 process Effects 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
210000004087 cornea Anatomy 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
229950010131 puromycin Drugs 0.000 description 7
230000009467 reduction Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000000744 eyelid Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
239000004205 dimethyl polysiloxane Substances 0.000 description 5
238000004987 plasma desorption mass spectroscopy Methods 0.000 description 5
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
239000000725 suspension Substances 0.000 description 5
210000001258 synovial membrane Anatomy 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
-1 Gal-GalNAc oligosaccharide Chemical class 0.000 description 4
238000005299 abrasion Methods 0.000 description 4
210000001188 articular cartilage Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
239000000975 dye Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000011347 resin Substances 0.000 description 4
230000000284 resting effect Effects 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
241000353097 Molva molva Species 0.000 description 3
102000005348 Neuraminidase Human genes 0.000 description 3
108010006232 Neuraminidase Proteins 0.000 description 3
241001597008 Nomeidae Species 0.000 description 3
229930182473 O-glycoside Natural products 0.000 description 3
150000008444 O-glycosides Chemical class 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000001976 enzyme digestion Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000007943 implant Substances 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000011068 loading method Methods 0.000 description 3
150000002772 monosaccharides Chemical class 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000005494 xerophthalmia Diseases 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108010022355 Fibroins Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000204031 Mycoplasma Species 0.000 description 2
241001460678 Napo <wasp> Species 0.000 description 2
241000906034 Orthops Species 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000007068 beta-elimination reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
MPVXINJRXRIDDB-VCDGYCQFSA-N dodecanoic acid;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCC(O)=O MPVXINJRXRIDDB-VCDGYCQFSA-N 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002706 hydrostatic effect Effects 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical group CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
230000008520 organization Effects 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
238000004321 preservation Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000010926 purge Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000003786 sclera Anatomy 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000009182 swimming Effects 0.000 description 2
238000004885 tandem mass spectrometry Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
238000012795 verification Methods 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000208340 Araliaceae Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000207447 Estrella Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000551546 Minerva Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
108010082913 S-layer proteins Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000004830 Super Glue Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000005946 Xerostomia Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000005611 electricity Effects 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
235000008434 ginseng Nutrition 0.000 description 1
239000003292 glue Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000001501 megacaryocyte Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000029052 metamorphosis Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
210000000299 nuclear matrix Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
210000004417 patella Anatomy 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000012925 reference material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010008 shearing Methods 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000012549 training Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Marine Sciences & Fisheries (AREA)
Ophthalmology & Optometry (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN201480065482.7A 2013-10-22 2014-10-22 重组润滑素的制备 Pending CN105899527A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361894366P	2013-10-22	2013-10-22
US61/894,366		2013-10-22
PCT/US2014/061827 WO2015061488A1 (en)	2013-10-22	2014-10-22	Production of recombinant lubricin

Publications (1)

Publication Number	Publication Date
CN105899527A true CN105899527A (zh)	2016-08-24

Family

ID=52993344

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201480065482.7A Pending CN105899527A (zh)	2013-10-22	2014-10-22	重组润滑素的制备

Country Status (22)

Country	Link
US (5)	US9982027B2 (sl)
EP (2)	EP3060577B1 (sl)
JP (2)	JP6669649B2 (sl)
KR (1)	KR102488928B1 (sl)
CN (1)	CN105899527A (sl)
AU (2)	AU2014340080B2 (sl)
BR (1)	BR112016008923A2 (sl)
CA (1)	CA2927949A1 (sl)
CY (1)	CY1124861T1 (sl)
DK (1)	DK3060577T3 (sl)
ES (1)	ES2891331T3 (sl)
HR (1)	HRP20211497T1 (sl)
HU (1)	HUE056397T2 (sl)
IL (2)	IL245236B (sl)
LT (1)	LT3060577T (sl)
MX (2)	MX380735B (sl)
PL (1)	PL3060577T3 (sl)
PT (1)	PT3060577T (sl)
RU (1)	RU2758115C2 (sl)
SG (2)	SG10201913598TA (sl)
SI (1)	SI3060577T1 (sl)
WO (2)	WO2015060935A1 (sl)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109055426A (zh) *	2018-08-06	2018-12-21	苏州迈缔姆生物技术有限公司	一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
CN115154667A (zh) *	2022-06-27	2022-10-11	天津大学	一种基于重组润滑素蛋白修饰的胶原蛋白基质的制备方法
CN115177790A (zh) *	2022-06-27	2022-10-14	天津大学	透明质酸和润滑素蛋白协同修饰胶原蛋白基质的制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3110817C (en)	2009-05-22	2023-08-15	Lubris, Llc	Application and uses of prg4 and therapeutic modulation thereof
EP2948553B1 (en) *	2013-01-25	2020-04-01	Baylor College Of Medicine	A helper-dependent adenoviral gene therapy delivery and expression system
WO2015060935A1 (en)	2013-10-22	2015-04-30	Lubris, Llc	Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja)	2013-11-26	2019-09-04	ルブリス，エルエルシー．	細胞間相互作用を阻害するための組成物及び方法
ES2808199T3 (es)	2015-01-26	2021-02-25	Lubris Llc	Uso de PRG4 como un agente antiinflamatorio
DK3300482T3 (da)	2015-05-19	2021-10-18	Lubris Llc	Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer
EP3563894B1 (en)	2018-05-04	2021-12-22	Boehringer Ingelheim International GmbH	Nebulizer and container
EP3911355A4 (en)	2019-01-15	2022-06-01	Cornell University	RECOMBINANT LUBRICINS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2020247440A1 (en) *	2019-06-03	2020-12-10	Lubris Llc	Use of prg4 to treat cancer
JP2023515504A (ja)	2020-02-24	2023-04-13	ノバルティスアーゲー	組み換え産生されたポリペプチドの精製
US20250282981A1 (en)	2022-04-27	2025-09-11	Lubris Llc	Methods of making polymer films

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040072741A1 (en) *	1999-04-23	2004-04-15	Jay Gregory D.	Tribonectin polypeptides and uses thereof
US20080287369A1 (en) *	2004-07-23	2008-11-20	Jay Gregory D	Compositions and Methods for Viscosupplementation
CN102575264A (zh) *	2009-09-18	2012-07-11	瑟莱克斯公司	增加的转基因表达和加工的产品和方法
CN102924584A (zh) *	2003-08-14	2013-02-13	惠氏公司	重组润滑素分子及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0953041A4 (en) *	1996-08-30	2003-01-29	Life Technologies Inc	SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US6530956B1 (en) *	1998-09-10	2003-03-11	Kevin A. Mansmann	Resorbable scaffolds to promote cartilage regeneration
US6743774B1 (en)	1999-04-23	2004-06-01	Rhode Island Hospital	Tribonectins
US7001881B1 (en)	1999-04-23	2006-02-21	Rhode Island Hospital	Tribonectins
SG141239A1 (en)	2001-01-26	2008-04-28	Selexis Sa	Matrix attachment regions and methods for use thereof
TW200307011A (en)	2002-04-18	2003-12-01	Chugai Pharmaceutical Co Ltd	Hyaluronic acid modifier
US7415381B2 (en)	2003-01-09	2008-08-19	Rhode Island Hospital, A Lifespan Partner	Joint friction sensing
US20060240037A1 (en)	2003-06-04	2006-10-26	Edward Fey	Methods and compositions for the treatment and prevention of degenerative joint disorders
EP2298898B1 (en)	2003-10-24	2012-12-26	Selexis S.A.	High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
WO2005102363A2 (en) *	2004-04-20	2005-11-03	Mucosal Therapeutics Llc	Methods of promoting cartilage healing or cartilage integration
EP1827478A4 (en)	2004-12-03	2009-08-05	Mucosal Therapeutics Llc	METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en)	2005-05-05	2007-05-17	Jay Gregory D	Methods of detecting lubricin
RU2008113439A (ru)	2005-09-09	2009-10-20	Лабофарм Инк. (CA)	Композиции с замедленным высвобождением лекарственного средства
EP2061883A2 (en) *	2006-08-23	2009-05-27	Selexis S.A.	Matrix attachment regions (mars) for increasing transcription and uses thereof
CA2664944C (en)	2006-09-28	2016-06-14	Hadasit Medical Research Services & Development Limited	Use of glycerophospholipids for joint lubrication
WO2008143816A1 (en)	2007-05-15	2008-11-27	Mucosal Therapeutics	Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en)	2007-09-12	2009-03-12	Mucosal Therapeutics	Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en)	2007-09-18	2009-04-23	Jay Gregory D	Treatment and prevention of joint disease
EP2915529B1 (en)	2008-05-07	2017-06-14	The Regents of The University of California	Therapeutic replenishment and enrichment of ocular surface lubrication
US8506944B2 (en)	2008-05-07	2013-08-13	The Regents Of The University Of California	Replenishment and enrichment of ocular surface lubrication
CN102438645A (zh)	2009-01-13	2012-05-02	卢布里斯有限责任公司	阴道上皮界面润滑的治疗调节
CA3110817C (en)	2009-05-22	2023-08-15	Lubris, Llc	Application and uses of prg4 and therapeutic modulation thereof
WO2011019963A2 (en)	2009-08-13	2011-02-17	Singularis, Inc.	Prg4 treatment for interstitial cystitis
US11213566B2 (en)	2010-01-19	2022-01-04	Lubris Llc	Oral care compositions and methods
US20130116186A1 (en)	2011-10-04	2013-05-09	Rhode Island Hospital, A Lifespan Partner	Lubricin injections to maintain cartilage health
WO2015060935A1 (en)	2013-10-22	2015-04-30	Lubris, Llc	Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja)	2013-11-26	2019-09-04	ルブリス，エルエルシー．	細胞間相互作用を阻害するための組成物及び方法
US20180161393A1 (en)	2015-01-26	2018-06-14	Lubris Llc	Prg4 for treating gout and its symptoms
ES2808199T3 (es)	2015-01-26	2021-02-25	Lubris Llc	Uso de PRG4 como un agente antiinflamatorio
DK3300482T3 (da)	2015-05-19	2021-10-18	Lubris Llc	Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer
US20170312335A1 (en)	2015-12-30	2017-11-02	Lubris Llc	Topical use of prg4 for treatment of allergy and symptoms of inflammation

2014
- 2014-08-22 WO PCT/US2014/052272 patent/WO2015060935A1/en not_active Ceased
- 2014-08-22 US US15/028,752 patent/US9982027B2/en active Active
- 2014-10-22 PL PL14856188T patent/PL3060577T3/pl unknown
- 2014-10-22 AU AU2014340080A patent/AU2014340080B2/en active Active
- 2014-10-22 SG SG10201913598TA patent/SG10201913598TA/en unknown
- 2014-10-22 MX MX2016005302A patent/MX380735B/es unknown
- 2014-10-22 RU RU2016119532A patent/RU2758115C2/ru active
- 2014-10-22 CN CN201480065482.7A patent/CN105899527A/zh active Pending
- 2014-10-22 US US15/030,825 patent/US10125180B2/en active Active
- 2014-10-22 KR KR1020167013154A patent/KR102488928B1/ko active Active
- 2014-10-22 LT LTEPPCT/US2014/061827T patent/LT3060577T/lt unknown
- 2014-10-22 HU HUE14856188A patent/HUE056397T2/hu unknown
- 2014-10-22 EP EP14856188.9A patent/EP3060577B1/en active Active
- 2014-10-22 HR HRP20211497TT patent/HRP20211497T1/hr unknown
- 2014-10-22 WO PCT/US2014/061827 patent/WO2015061488A1/en not_active Ceased
- 2014-10-22 BR BR112016008923A patent/BR112016008923A2/pt not_active Application Discontinuation
- 2014-10-22 SI SI201431882T patent/SI3060577T1/sl unknown
- 2014-10-22 CA CA2927949A patent/CA2927949A1/en active Pending
- 2014-10-22 PT PT14856188T patent/PT3060577T/pt unknown
- 2014-10-22 JP JP2016525090A patent/JP6669649B2/ja active Active
- 2014-10-22 DK DK14856188.9T patent/DK3060577T3/da active
- 2014-10-22 EP EP21183527.7A patent/EP3971203A1/en not_active Withdrawn
- 2014-10-22 SG SG11201603151VA patent/SG11201603151VA/en unknown
- 2014-10-22 ES ES14856188T patent/ES2891331T3/es active Active
2016
- 2016-04-20 IL IL245236A patent/IL245236B/en unknown
- 2016-04-22 MX MX2021003243A patent/MX2021003243A/es unknown
2018
- 2018-11-07 US US16/183,497 patent/US10723773B2/en active Active
2019
- 2019-03-04 AU AU2019201478A patent/AU2019201478B2/en active Active
- 2019-11-18 JP JP2019207908A patent/JP6970164B2/ja active Active
2020
- 2020-06-18 US US16/904,978 patent/US11485764B2/en active Active
2021
- 2021-05-25 IL IL283447A patent/IL283447A/en unknown
- 2021-10-06 CY CY20211100872T patent/CY1124861T1/el unknown
2022
- 2022-10-27 US US17/975,572 patent/US12435115B2/en active Active

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040072741A1 (en) *	1999-04-23	2004-04-15	Jay Gregory D.	Tribonectin polypeptides and uses thereof
CN102924584A (zh) *	2003-08-14	2013-02-13	惠氏公司	重组润滑素分子及其用途
US20080287369A1 (en) *	2004-07-23	2008-11-20	Jay Gregory D	Compositions and Methods for Viscosupplementation
CN102575264A (zh) *	2009-09-18	2012-07-11	瑟莱克斯公司	增加的转基因表达和加工的产品和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SELEXIS: "Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic", 《HTTP://SELEXIS.COM/SELEXIS-LUBRIS-PARTNERSHIP-ADVANCES-DIFFICULT-EXPRESS-PROTEIN-TOWARDS-CLINIC/》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109055426A (zh) *	2018-08-06	2018-12-21	苏州迈缔姆生物技术有限公司	一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
CN109055426B (zh) *	2018-08-06	2021-06-25	智享生物(苏州)有限公司	一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
CN115154667A (zh) *	2022-06-27	2022-10-11	天津大学	一种基于重组润滑素蛋白修饰的胶原蛋白基质的制备方法
CN115177790A (zh) *	2022-06-27	2022-10-14	天津大学	透明质酸和润滑素蛋白协同修饰胶原蛋白基质的制备方法

Also Published As

Publication number	Publication date
EP3060577B1 (en)	2021-07-07
SG10201913598TA (en)	2020-02-27
US12435115B2 (en)	2025-10-07
IL245236B (en)	2021-12-01
RU2016119532A (ru)	2017-11-28
HRP20211497T1 (hr)	2021-12-24
EP3060577A4 (en)	2017-05-17
JP2016535590A (ja)	2016-11-17
RU2758115C2 (ru)	2021-10-26
US20190270783A1 (en)	2019-09-05
KR102488928B1 (ko)	2023-01-13
RU2016119532A3 (sl)	2018-05-16
US10723773B2 (en)	2020-07-28
IL245236A0 (en)	2016-06-30
BR112016008923A2 (pt)	2017-09-19
US20160250286A1 (en)	2016-09-01
AU2019201478A1 (en)	2019-03-28
PL3060577T3 (pl)	2022-01-24
AU2014340080B2 (en)	2018-12-06
US20210130427A1 (en)	2021-05-06
SI3060577T1 (sl)	2021-12-31
DK3060577T3 (da)	2021-10-04
LT3060577T (lt)	2021-12-27
JP2020039348A (ja)	2020-03-19
WO2015060935A1 (en)	2015-04-30
SG11201603151VA (en)	2016-05-30
US9982027B2 (en)	2018-05-29
MX2021003243A (es)	2021-05-12
EP3971203A1 (en)	2022-03-23
PT3060577T (pt)	2021-10-01
US10125180B2 (en)	2018-11-13
JP6970164B2 (ja)	2021-11-24
CY1124861T1 (el)	2022-11-25
AU2019201478B2 (en)	2021-07-08
IL283447A (en)	2021-07-29
HUE056397T2 (hu)	2022-02-28
CA2927949A1 (en)	2015-04-30
US20230234999A1 (en)	2023-07-27
JP6669649B2 (ja)	2020-03-18
WO2015061488A1 (en)	2015-04-30
EP3060577A1 (en)	2016-08-31
US11485764B2 (en)	2022-11-01
KR20160086843A (ko)	2016-07-20
MX380735B (es)	2025-03-12
US20160304572A1 (en)	2016-10-20
ES2891331T3 (es)	2022-01-27
MX2016005302A (es)	2017-02-15
AU2014340080A1 (en)	2016-06-02

Publication	Publication Date	Title
CN105899527A (zh)	2016-08-24	重组润滑素的制备
Scott	1995	Extracellular matrix, supramolecular organisation and shape
Garcia et al.	2018	Techno-functional properties of crude extracts from the green microalga Tetraselmis suecica
Bishop	2000	Structural macromolecules and supramolecular organisation of the vitreous gel
DE60031456T2 (de)	2007-08-23	Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
Rana et al.	2023	Collagen-based hydrogels for the eye: a comprehensive review
DE60027562T2 (de)	2006-11-02	Hyaluronidase aus hirudinaria manillensis, isolierung, reinigung, und rekombinante herstellung
Cassoni et al.	2018	Novel eco-friendly method to extract keratin from hair
CN106906196A (zh)	2017-06-30	可溶性透明质酸酶的大规模生产
DE60207053T2 (de)	2006-04-20	Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
KR20080004473A (ko)	2008-01-09	가용성 글리코사미노글리카나제와 가용성글리코사미노글리카나제의 제조 및 사용 방법
Yang et al.	2020	Selective complex coacervation of pea whey proteins with chitosan to purify main 2S albumins
CN100374157C (zh)	2008-03-12	N-乙酰半乳糖胺-4-硫酸酯酶前体,以及生产和纯化所述酶的方法
JP6823231B2 (ja)	2021-02-03	自己組織化ペプチドおよびそれから形成されるゲル
Potter et al.	2018	Effects of differing purification methods on properties of keratose biomaterials
CN102294198A (zh)	2011-12-28	一种可调控的未变性天然胶原表面活性剂及其制备方法
Fernàndez-Busquets	2008	The sponge as a model of cellular recognition
TWI337868B (en)	2011-03-01	Method for extracting extract from chaenomeles lagenaria and the applications thereof
Kefalides	1977	Basement membranes
Bond et al.	2001	Expression and purification of the extracellular domain of human myelin protein zero
KR20230077352A (ko)	2023-06-01	히알루론산나트륨을 포함하는 화장료 조성물
CN117177742A (zh)	2023-12-05	溶酶体相关膜蛋白靶向化合物及其用途
Ermakova et al.	2008	Proteoglycans of L6J1 myoblast extracellular matrix: Properties and effect on myoblast adhesion

Legal Events

Date	Code	Title
2016-08-24	C06	Publication
2016-08-24	PB01	Publication
2017-01-04	C10	Entry into substantive examination
2017-01-04	SE01	Entry into force of request for substantive examination